Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Expenses (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Accumulated Expenses for 8 consecutive years, with $14.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 62.15% year-over-year to $14.9 million, compared with a TTM value of $14.9 million through Sep 2025, down 62.15%, and an annual FY2024 reading of $16.3 million, down 48.36% over the prior year.
  • Accumulated Expenses was $14.9 million for Q3 2025 at Bicycle Therapeutics, up from $11.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $39.3 million in Q3 2024 and bottomed at $2.7 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $15.7 million, with a median of $11.1 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses soared 494.27% in 2024, then plummeted 76.05% in 2025.
  • Year by year, Accumulated Expenses stood at $6.4 million in 2021, then soared by 54.43% to $9.9 million in 2022, then soared by 217.38% to $31.5 million in 2023, then tumbled by 48.36% to $16.3 million in 2024, then decreased by 8.55% to $14.9 million in 2025.
  • Business Quant data shows Accumulated Expenses for BCYC at $14.9 million in Q3 2025, $11.3 million in Q2 2025, and $6.2 million in Q1 2025.